Phase II trial of doxorubicin and bortezomib in patients with incurable head and neck adenoid cystic carcinoma

Trial Profile

Phase II trial of doxorubicin and bortezomib in patients with incurable head and neck adenoid cystic carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Bortezomib (Primary) ; Doxorubicin
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 08 Jun 2010 Study details were reported at ASCO 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top